AIMS: The debate on the funding and availability of cytotoxic drugs raises questions about
the contribution of curative or adjuvant cytotoxic chemotherapy to survival in adult cancer …

Simple Summary Non-Hodgkin lymphoma (NHL) is one of the most frequent HIV-related
neoplasms, and diffuse large B-cell lymphoma (DLBCL) is the most common subtype. In …

Background To determine the incidence of early cardiotoxicity induced by the CHOP
regimen in patients with aggressive non-Hodgkin's lymphoma (NHL) and to identify …

PURPOSE: To estimate the cost-effectiveness from a French payer perspective of CHOP
(cyclophosphamide, doxorubicin, vincristine, and prednisone) alone compared with CHOP …

For the last decade, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)
has been the best available standard of care for aggressive non-Hodgkin's lymphoma …

The role of adjuvant radiotherapy to sites of nodal bulky disease in patients with aggressive
diffuse large cell lymphoma (DLCL), and stage IV remain undefined. We began a …

Background CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) is
accepted as the best available standard treatment for first-line chemotherapy in aggressive …

The present study assessed several parameters of cardiopulmonary function in patients,
after treatment for aggressive non-Hodgkin's lymphoma and Hodgkin's disease, to …

PURPOSE: In this randomized phase II study, we evaluated the efficacy of semustine added
to CEOP regimen as induction chemotherapy in patients with stage IE/IIE extranodal NK/T …

The overall percentage of patients achieving long-term remissions in aggressive non-
Hodgkin's lymphoma (NHL) using CHOP or CHOP-based primary chemotherapy is only …